U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141706) titled 'A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors' on Aug. 18.
Brief Summary: This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes up to 3 randomized dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced/Metastatic Solid Tumors
Intervention:
DRUG: DB-1317
Administered I.V.
Recruitment Status:...